| 2023 |
Polgreen LE, Imel EA, Econs MJ. Autosomal dominant osteopetrosis. Bone. May 2023;170:116723. |
1 |
1 |
| 2021 |
Imel EA. Congenital conditions of hypophosphatemia in children. Calcif Tiss Int. January 2021;108(1):74-90. |
0 |
0 |
| 2021 |
Padidela R, Whyte MP, Glorieux FH, Munns CF, Ward LM, Nilsson O, Portale AA, Simmons JH, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Williams A, Nixon A, Sun W, Chen A, Skrinar A, Imel EA. Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with x-linked hypophosphatemia. Calcif Tiss Int. May 2021;108(5):622-633. |
0 |
0 |
| 2011 |
Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to x-linked hypophosphatemia. J Bone Miner Res. July 2011;26(7):1381-1388. |
18 |
15 |
| 2020 |
Imel EA, Liu Z, Coffman M, Acton D, Mehta R, Econs MJ. Oral iron replacement normalizes fibroblast growth factor 23 in iron‐deficient patients with autosomal dominant hypophosphatemic rickets. J Bone Miner Res. February 2020;35(2):231-238. |
5 |
4 |
| 2020 |
Imel EA, Starzyk K, Gliklich R, Weiss RJ, Wang Y, Williams SA. Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis. Osteoporos Int. December 2020;31(12):2413-2424. |
0 |
0 |